The vasopressin V1b receptor antagonist, SSR149415, and the corticotrophin-releasing factor1 (CRF1) receptor antagonist, SSR125543, have antidepressant-like effects on the DRL 72s schedule

被引：0
|
作者：
Cohen, C [1 ]
Louis, C [1 ]
O'Donnell, JM [1 ]
Griebel, G [1 ]
机构：
[1] Sanofi Synthelabo, Psychopharmacol, Bagneux, France
来源：
NEUROPSYCHOPHARMACOLOGY | 2004年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S95 / S95
页数：1
相关论文
共 42 条
  • [21] Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
    Griebel, G
    Simiand, J
    Gal, CSL
    Wagnon, J
    Pascal, M
    Scatton, B
    Maffrand, JP
    Soubrié, P
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (09) : 6370 - 6375
  • [22] SSR149415, a V1b receptor antagonist, inhibits stress-induced visceral hypersensitivity in rats
    Ferrier, Laurent
    Gaultier, Eric
    Gal, Claudine Serradeil-Le
    Pascal, Marc
    Bueno, Lionel
    GASTROENTEROLOGY, 2008, 134 (04) : A544 - A544
  • [23] V1b Receptor Antagonist SSR149415 and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice
    Zhou, Yan
    Rubinstein, Marcelo
    Low, Malcolm J.
    Kreek, Mary Jeanne
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2018, 42 (01) : 195 - 205
  • [24] SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model
    Breuer, M. E.
    van Gaalen, M. M.
    Wernet, W.
    Claessens, S. E. F.
    Oosting, R. S.
    Behl, B.
    Korte, S. M.
    Schoemaker, H.
    Gross, G.
    Olivier, B.
    Groenink, L.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 (01) : 101 - 106
  • [25] SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model
    M. E. Breuer
    M. M. van Gaalen
    W. Wernet
    S. E. F. Claessens
    R. S. Oosting
    B. Behl
    S. M. Korte
    H. Schoemaker
    G. Gross
    B. Olivier
    L. Groenink
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379 : 101 - 106
  • [26] Effects of the CRF1 receptor antagonist SSR125543 on energy balance and food deprivation-induced neuronal activation in obese Zucker rats
    Doyon, Christian
    Samson, Pierre
    Lalonde, Josee
    Richard, Denis
    JOURNAL OF ENDOCRINOLOGY, 2007, 193 (01) : 11 - 19
  • [27] The Non-Peptide Vasopressin V1b Receptor Antagonist, SSR149415, Ameliorates Spermatogenesis Function in a Mouse Model of Chronic Social Defeat Stress
    Wang, Bin
    Zhou, Jian
    Zhuang, Yan-Yan
    Wang, Liang-Liang
    Pu, Jin-Xian
    Huang, Yu-Hua
    Xia, Fei
    Lv, Jin-Xing
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (11) : 3891 - 3898
  • [28] Chronic treatment with the vasopressin 1b receptor antagonist SSR149415 prevents the dysphoria associated with nicotine withdrawal in rats
    Qi, Xiaoli
    Guzhva, Lidia
    Ji, Yue
    Bruijnzeel, Adriaan W.
    BEHAVIOURAL BRAIN RESEARCH, 2015, 292 : 259 - 265
  • [29] Reduction by SSR125543A, a CRF1 receptor antagonist, of schedule-induced polydipsia suggests an anti-stress action in this procedure
    Pério, A
    Depoortère, R
    Griebel, G
    Soubrié, P
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S366 - S366
  • [30] V1B/CRF1 receptor heterodimerisation as a key mechanism of vasopressin and corticotropin-releasing factor synergism
    Mion, J.
    Boulay, V.
    Millan, M. J.
    Guillon, G.
    Corbani, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S9 - S10
12345